Vertical transmission of HIV is preventable, and we have a duty to ensure the burden of HIV is not handed down across generations.
The DolPHIN 2 programme investigates the safe and effective use of dolutegravir for women who present with untreated HIV in late pregnancy
The team at the Infectious Diseases Institute, Kampala
DolPHIN 2 is a multinational project led by the University of Liverpool which aims to reduce the rate of vertical transmission of HIV through research into a new HIV drug called dolutegravir.
Read about the challenges that the DolPHIN 2 project seeks to address and why.
Learn more about our multinational research consortium, comprising partners in Europe and sub-Saharan Africa.
Collaboration with the community is at the heart of DolPHIN 2. Click here to learn more about our community engagement, and to hear from some of our study participants.
The DolPHIN 2 consortium is a multinational partnership comprising five research organisations and our funder, Unitaid.